Androgens are important growth regulators in prostate cancer. Their known mode of action in target cells requires binding to a cytoplasmic androgen receptor followed by a nuclear translocation event and modulation of the expression of speci®c genes. Here, we report another mode of action of this receptor. Treatment of androgen responsive prostate cancer cells with dihydrotestosterone leads to a rapid and reversible activation of mitogen-activated protein kinases MAPKs (also called extracellular signal-regulated kinases or Erks). Transient transfection assays demonstrated that the androgen receptor-mediated activation of MAP kinase results in enhanced activity of the transcription factor Elk-1. This action of the androgen receptor diers from its known transcriptional activity since it is rapid and insensitive to androgen antagonists such as hydroxy¯utamide or casodex. Biochemical studies as well as analyses with dominant negative mutants showed the involvement of kinases such as MAPK/Erk kinase, phosphatidyl-inositol 3-kinase and protein kinase C in the androgen receptormediated activation of MAP kinase. These results demonstrate a novel regulatory action of the androgen receptor and prove that in addition to its known transcriptional eects, it also uses non-conventional means to modulate several cellular signalling processes.
Introduction
Androgens are the major regulators of prostate growth (Cunha et al., 1987) . Their known eects are mediated by a cytoplasmic androgen receptor (AR) that is translocated into the nucleus upon hormone binding to positively or negatively modulate the expression of speci®c genes (Beato et al., 1995) .
Transcriptional upregulation by the AR occurs through homodimer binding of the receptor to distinct DNA sequences (Cato et al., 1987; Ham et al., 1988; Beato, 1989) . This takes place alongside interaction of the receptor with basal transcription factors such as TFIIF and the TATA-box binding protein (McEwan and Gustafsson, 1997) or with coactivators that potentiate its activity (Voegel et al., 1996; Yeh and Chang, 1996) . The AR also negatively regulates the expression of genes through interaction with transcription factors already bound to DNA. For example, it interacts with c-Jun to inhibit the DNA binding activity of this factor (Kallio et al., 1995) or with Ets transcription factors to downregulate their activities (Schneikert et al., 1996) .
The ability to regulate gene expression positively and negatively is not speci®c to the AR but is shared by other steroid receptors (Beato et al., 1995) . In addition, a number of steroid hormones are reported to rapidly and reversibly activate important intermediates in signal transduction pathways known to trigger cell proliferation (Migliaccio et al., , 1998 Endoh et al., 1997; Marcinkowska et al., 1997) . For example estrogens activate two members in the family of c-srcrelated tyrosine kinases, c-src and c-yes as well as the MAP kinases Erk-1 and -2 (Di . Progestins also activate MAP kinase, a reaction that has been correlated with an indirect association of the progesterone receptor (PR) with c-src through the intermediary role of the estrogen receptor (ER) (Migliaccio et al., 1998) . Interaction of the PR and ER with c-src either directly or indirectly enhances the kinase activity of this protein which then activates MAP kinase via the Ras-Raf-1 pathway (Castoria et al., 1999) . Other mechanisms have been proposed to explain the ER-mediated activation of MAP kinase. In one report it was shown that it occurs via the release of calcium from intracellular stores (Improta-Brears et al., 1999) . Another study on the mechanism of ERmediated activation of MAP kinase showed the involvement of Gaq and Gas proteins (Razandi et al., 1999) . Thus the ability of ER to activate MAP kinase seems to involve several dierent signalling pathways.
In this communication, we report that the AR also activates MAP kinase. This occurs through an early and a late response pathway in a cell-type dependent manner. We have in this report analysed the rapid response and shown with the use of kinase inhibitors and dominant negative mutants that it is mechanistically dierent from that mediated by the ER and PR. The AR action requires in addition to MAPK/Erk kinase, the phosphatidyl-inositol 3-kinase and protein kinase C pathways. Unlike the eects of the ER and PR which are inhibited by hormone antagonists, the AR response is insensitive to dierent antiandrogens. We therefore report here a rapid cellular signalling response which appears to be speci®c for the AR. a novel non-conventional mechanism (Migliaccio et al., , 1998 Endoh et al., 1997; Marcinkowska et al., 1997) . In this study we have asked whether androgens also mediate this response using two primary androgen responsive cells: human genital skin ®broblasts and prostatic stromal cells. Both cell lines were treated with the androgen dihydrotestosterone (DHT) and MAP kinase activity was determined by immunoblotting cellular extracts with antibodies that recognize active dually phosphorylated MAP kinases Erk-1 and -2.
In the primary human genital skin ®broblasts, increased phosphorylation of Erk-1 and -2 was detected after 16 h of hormone treatment. This persisted several hours before ®nally returning to basal levels after 30 h (Figure 1a , compare lanes 6 ± 9 with lane 1; Phospho p44 and p42 column). During this time, AR level was increased possibly due to an androgen-mediated post-translational stabilization process but no change in the amount of nonphosphorylated Erk-1 and -2 was observed ( Figure  1a) . A rapid (10 ± 30 min) activation of Erk-1 and -2 was not observed in these primary human genital skin ®broblasts ( Figure 1b ) although a 10 min exposure to phorbol ester 12-O-tetradecanoyl 13-acetate (TPA) activated the MAP kinases ( Figure  1b ). The lack of rapid activation of Erk-1 and -2 by DHT was not a special feature of the primary human genital skin ®broblasts. Several cells into which we transiently transfected the AR also failed to show this response upon DHT treatment (results not shown).
A dierent result was obtained in primary prostatic stromal cells. The basal level of Erk-1 and -2 phosphorylation was low ( Figure 1c , lane 1) but this was rapidly and transiently increased (2 ± 60 min) by DHT treatment (Figure 1c , lanes 2 ± 5). Two further peaks of phosphorylated Erk-1 and -2 were observed at 8 ± 20 h and again at 30 h ( Figure 1c , lanes 8 ± 12). The level of the AR and nonphosphorylated Erk-1 and -2 remained the same throughout the experiment. Early and late peaks of phosphorylation of Erk-1 and -2 following treatment with DHT were also observed in the androgen receptor negative human prostate PC3 cells into which we stably transfected the wild-type AR while only the early peak was detected in the androgen responsive human LNCaP prostate cancer cells (Figure 1d ). The signi®cance of these cell-type speci®c dierences is so far not clear. In subsequent studies we further characterized the rapid eect of DHT on MAP kinase activation in the prostate cells.
Ligand speci®city
PC3 cells stably transfected with an empty or an ARexpressing vector were treated for dierent lengths of time with DHT and MAP kinase activity was determined. MAP kinase was immunoprecipitated from the cellular extracts and subjected to an in vitro kinase assay with the use of myelin basic protein as substrate. In these analyses, a transient activation of MAP kinase was observed between 2 and 30 min in the AR-positive cells but no clear activation was detected in cells transfected with the empty expression vector ( Figure 2a) . As a control, both cell lines responded to TPA treatment by an increased MAP kinase activity (Figure 2a) . These results show that the rapid DHTmediated activation of Erk-1 and -2 is strictly dependent on the presence of the AR. Figure 1 Kinetics of DHT-mediated phosphorylation of Erk-1 and -2 in primary genital skin ®broblasts and in primary prostatic stromal cells. Immunoblots were carried out with equal amounts of cellular proteins from primary genital skin ®broblasts after treatment with (a) 100 nM DHT for the indicated period of time or with (b) 100 nM DHT or 80 ng/ml TPA. (c) Immunoblots were also carried out with equal amounts of cellular proteins from human primary prostatic smooth muscle cells treated for the indicated period of time with 100 nM DHT. The ®lters were hybridized with antibodies against the human androgen receptor (AR), phosphorylated Erk-1 and -2 (phospho p42/p44) and nonphosphorylated Erk-1 and -2 (p42/p44). The sign (7) Concentrations of DHT as low as 0.1 nM suced for the activation of Erk-1 and -2 in both PC3 ARwt and LNCaP cells (Figure 2b, upper panel) and correlated well with the doses required for transactivation of a transiently transfected AR-responsive MMTV reporter construct in these cells (Figure 2b, lower panel) . Note that due to unequal transfection eciencies, the level of DHT-mediated activation of the MMTV construct in these two cell lines is strikingly dierent.
Dierences were observed in the androgen-mediated transactivation and rapid activation of Erk-1 and -2. While transactivation is downregulated by the antiandrogens hydroxy¯utamide and casodex (Cato et al., 1987; Berrevoets et al., 1993) , DHT-mediated activation of Erk-1 and -2 is insensitive to the action of these antagonists at equimolar or 100-fold molar excess concentrations (100 nM and 10 mM) (Figure 2c ). The lack of inhibitory action by the antiandrogens is most likely due to their inherent ability to activate Erk-1 and -2 (Figure 2d ). This response is mediated by the AR as no activation was observed in PC3 cells transfected with an empty expression vector (results not shown). The DHT or antiandrogen-mediated activation of Erk-1 and -2 is speci®c for this class of MAP kinase as other MAP kinases such as p38 or JNK-1 and -2 were not activated although anisomycin which was used as a control (Kortenjann and Shaw, 1995) activated these kinases ( Figure 2c ).
Downstream eector molecules
Upon activation, Erk-1 and -2 become translocated from the cytoplasm into the nucleus where they enhance the activity of speci®c eector molecules such as the transcription factor Elk-1 (Marias et al., 1993; Gille et al., 1995a; Yang et al., 1998) . We therefore investigated whether Elk-1 was activated by DHT treatment. This was determined through transient transfection of a construct containing the DBD of the yeast Gal 4 transcription factor fused to Elk-1 and an indicator gene carrying Gal 4 binding sites into PC3 cells.
In the presence of Gal 4 DBD, the reporter activity was low in the AR negative PC3 cells and was neither enhanced by DHT nor by the epidermal growth factor (EGF), a known activator of the Erk-1 and -2 signalling pathway (Ahn et al., 1991) . In the presence of the Gal 4 DBD-Elk-1, the basal promoter activity in the PC3 cells was slightly increased possibly due to residual growth factors in the culture medium that activated the Elk-1 protein (Figure 3a ). This activity was further enhanced threefold by EGF but not by DHT (Figure 3a) . In cells additionally cotransfected with the AR, the basal level was even higher possibly + RNA was prepared and 10 mg were used for Northern blot analyses with radioactively labelled Fos- (Curran et al., 1982) and GAPDH-speci®c (Fort et al., 1985) DNA probes due to the eect of residual androgens activating the AR (Figure 3a) . The promoter activity in this case was not only enhanced 3 ± 4-fold by EGF but also by DHT (Figure 3a) .
To prove that this AR response is a non-classical transactivation function, the antiandrogens casodex and hydroxy¯utamide were analysed for their eects on Elk-1 activity. These antiandrogens do not normally activate transactivation via the wild-type AR but in this assay they enhanced the transcriptional activity of Elk-1 albeit to a lesser extent than DHT (Figure 3b ). This eect was dependent on the presence of the AR as the antiandrogens did not exert any in¯uence on Elk-1 activity in cells that lack the AR (Figure 3b) . As a control, EGF activated Elk-1 independent of the presence of the AR showing that its signalling action does not rely on the AR.
As Elk-1 transcriptionally activates c-fos expression (Gille et al., 1995a; Treisman, 1996) , we determined whether DHT can rapidly enhance the expression of this gene. In a Northern blot assay carried out with RNA from LNCaP cells, we showed that DHT transiently activates the expression of c-fos with the same kinetics as it activates Erk-1 and -2 (Figure 3c ; compare Northern blot assay with Figure 1d , bottom panel, lanes 1 ± 6). DHT did not activate the c-fos gene in PC3 cells transfected either with the AR or with the empty expression vector (results not shown). This is probably due to an insensitivity of this gene locus in the PC3 cells.
Sensitivity to kinase inhibitors
To identify the chain of events that accompany the DHT-mediated phosphorylation of Erk-1 and -2 and activation of Elk-1, we examined the eect of various kinase inhibitors on the response of the AR. We used the MAPK/ERK kinase inhibitor PD98059 (Dudley et al., 1995) , protein kinase C (PKC) inhibitor GF109203X (Toullect et al., 1991) , downregulation of PKC by prolonged treatment with phorbol esters (Fabbro et al., 1986) or phosphatidyl-inositol 3 (PI3) kinase inhibitor wortmannin (Ward et al., 1996) . All these inhibitors downregulated the activation of Erk-1 and -2 by DHT (Figure 4 , compare lanes 3 ± 6 with 2). As positive controls, the inhibitors were tested on known signalling pathways to con®rm their speci®city.
Figure 4 MEK, protein kinase C and phosphatidyl inositol-3 kinase are involved in dihydrotestosterone-induced phosphorylation of Erk-1 and -2. PC3 ARwt cells were treated with vehicle (0.1% ethanol) alone (lane 1) for 30 min or with 100 nM DHT for 30 min in the absence (lane 2) or presence of dierent inhibitors (lanes 3 ± 6). As controls, 5 ng/ml EGF (lanes 7 ± 10) or 80 ng/ml TPA (lanes 11 ± 14) were used alone as inducers for 10 min or in the presence of dierent inhibitors. The vehicle alone (0.1% DMSO) (lanes 1, 2, 7 and 11) or vehicle plus inhibitors were added 15 min before addition of DHT, EGF or TPA. The concentrations of the inhibitors used were 50 mM PD98059 (lanes 3 and 8), 500 nM GF109203X (lanes 4, 9 and 12) and 100 nM wortmannin (lanes 6, 10 and 14). In the case of prolonged treatment with TPA (lanes 5 and 13), the cells were incubated with this compound for 16 h prior to the addition of the inducers. After the various treatments, the cells were harvested and cellular proteins were prepared and used for immunoblots with the antiphospho-Erk antibody and an antibody against non-phosphorylated Erk The MEK inhibitor but not the inhibitor of PKC nor wortmannin abrogated EGF induced phosphorylation of Erk-1 and -2 (Figure 4 , compare lanes 8 ± 10 with 7). In further controls, phorbol ester (TPA)-induced phosphorylation of Erk-1 and -2 was suppressed by the PKC inhibitor or by prolonged treatment with TPA but not by the PI3 kinase inhibitor (Figure 4 , compare lanes 12 ± 14 with 11). These inhibitor studies suggest the involvement of the Raf-MEK, PI3 kinase and PKC pathways in the AR mediated activation of Erk-1 and -2.
To further con®rm the involvement of these pathways, we carried out Elk-1 transactivation studies with dominant negative constructs of Raf-1 and the p85 subunit of PI3 kinase (Bruder et al., 1992; Brennan et al., 1997) . These constructs did not only abrogate the DHT eect but they also reduced the basal activity which possibly arose as a result of residual hormone in the culture medium (Figure 5a) . A more direct link between these kinases and the DHT signalling pathway was established in the case of PI3 kinase in an in vitro kinase assay. In this study, PC3 ARwt cells, showed a low but clear increase in PI3 kinase activity following treatment with DHT or with IGF-I as a control (Figure 5b ). No increase in PI3 kinase activity was induced by DHT in PC3 cells lacking the AR (results not shown).
These results together demonstrate that the AR mediated activation of Erk-1 and -2 requires the activation of intermediary kinases that may either be downstream of the AR or whose activity may be required in parallel for transfer of signals from the AR to the MAP kinases.
Discussion
We have demonstrated in this work that activation of the AR by the androgen DHT leads to phosphorylation of Erk-1 and -2 via two pathways: rapid and late response pathways. We have analysed the rapid response to determine how it compares with other rapid eects of steroid hormone receptors in the activation of MAP kinase recently reported.
With the use of kinase inhibitors such as the MEK inhibitor PD98059 and a dominant negative mutant of Raf-1, we succeeded in blocking the rapid activation of MAP kinase by the AR demonstrating the involvement of the Raf-1-MEK pathway. This is in agreement with reports of ER and PR activating MAP kinase through the Ras-Raf-1-MEK pathway (Migliaccio et al., , 1998 . In addition, we have shown for the AR that PI3 kinase and PKC also contribute to the DHT-mediated activation of MAP kinase. These ®ndings were obtained by the use of kinase inhibitors and confirmed in the case of PI3 kinase with a dominant negative mutant and an in vitro kinase assay. From these studies we can conclude that the rapid response of the AR is mechanistically dierent from that reported for the other steroid receptors in that it requires additional signalling pathways. We also conclude that the AR is either upstream of Raf-1 and PI3 kinase or that these signalling pathways are activated in parallel such that their activities together contribute to the AR-mediated activation of MAP kinase. This latter idea comes from results of our DHT-mediated Elk-1 activation studies where dominant negative mutants inhibited not only the androgen response but also the basal activity of the indicator gene. This suggests the involvement of a basal activity for the manifestation of the DHT response.
In contrast to recent studies where it was shown that the ERb isoform rapidly activates Erk-1 and -2 as well as c-Jun kinase (Razandi et al., 1999) , in this present work we can only show a rapid eect of the AR on Erk-1 and -2. Other MAP kinases such as p38 or JNK-1 and -2 were not activated by the AR. A further dierence in the rapid mode of action of the AR compared to the other steroid receptors is its insensitivity to antihormones. Antiestrogens and antiprogestins inhibit the ER-and PR-mediated activation of MAP kinase Di Domenico et al., 1996) whereas in our studies antiandrogens are unable to inhibit the AR response.
We have identi®ed c-fos as one of the downstream targets of DHT-mediated activation of MAP kinase. In AR-positive LNCaP prostate cell line, activation of Erk-1 and -2 by DHT was correlated with an increased expression of this gene. Several other downstream targets may exist and one of them could be the AR itself since a dominant negative Erk-2 construct downregulated ligand-dependent transactivation by the receptor (Peterziel H and Cato ACB, unpublished) . This may therefore provide a means whereby the AR potentiates its own transactivation potential through activation of MAP kinase.
Other investigators have reported rapid eects of androgens such as increased intracellular calcium level or increased levels of inositol trisphosphates and diacylglycerol in osteoblasts and prostatic cells (Steinsapir et al., 1991; Lieberherr and Grosse, 1994) . These eects are very rapid (5 and 60 s) compared to the 2 ± 60 min response we have described here for activation of MAP kinase. As estrogen-induced activation of MAP kinase is reported to involve mobilization of intracellular calcium (Improta-Brears et al., 1999) , it is likely that these very rapid eects in intracellular calcium concentrations seen with androgens may preceed the activation of MAP kinase reported here in our work. This idea is being investigated at the moment.
We have demonstrated that rapid activation of MAP kinase by androgen occurs in cells of prostatic origin and not in genital skin ®broblasts. This suggests a rather restrictive tissue or organ speci®city for this AR response. The function of this increased MAP kinase activity is not clear at the moment but whatever it may be, it is certainly not essential for life as mice and humans lacking a functional androgen receptor will survive (He et al., 1991; Marcelli et al., 1991) . It is therefore likely that this increase in MAP kinase activity by the AR may be con®ned to particular patho-physiological situations at de®ned sites of androgen action.
It is interesting to note that the rapid action of androgen reported in osteoblasts (Lieberherr and Grosse, 1994 ) and what we have described here in prostatic cells are insensitive to antiandrogens. Thus the current therapeutically available antiandrogens may not be totally eective in abrogating all androgenic activity in target cells. This notion is consistent with ®ndings that long-term blockade of the growth promoting eects of androgen has so far not been achieved with antiandrogens. Cessation of antiandrogen therapy in certain cases even improve rather than worsen the symptoms of the patients (Scher and Kelly, 1993; Small and Carrol, 1994; Moul et al., 1995) . The rapid action of the AR that we have reported here may therefore provide a system for the identi®cation of a new class of antiandrogens which together with the classical androgen antagonists may be eective in completely abrogating the action of the AR.
Taken together these ®ndings de®ne a rapid action of AR that is mechanistically dierent from what has so far been described for other steroid receptors. The cell type speci®city of this response plus the known role of the activated kinases in cell proliferation, makes it an interesting regulatory pathway that requires further attention in future analyses of AR action.
Materials and methods

Materials and plasmid constructs
Phorbol ester (TPA) was purchased from Sigma Ltd. (Deisenhofen, Germany) and human recombinant epidermal growth factor (EGF) from Bachem (Bubendorf, Switzerland). Kinase inhibitors PD98059, GF109203X, and Wortmannin were all purchased from Calbiochem (Bad Soden/Taunus, Germany). The indicator gene consisting of GAL 4 DNA binding sites controlling the expression of a luciferase gene pG5.E4D38lux3, the expression vector containing the GAL 4 DNA binding domain (DBD) alone or linked to the transcription factor Elk-1, the empty expression vector containing the RSV promoter RSV-H20 and the RSV promoter driving the expression of a dominant negative Raf-1 sequence RSV-cRafC4 have all been described (Oringa et al., 1990; Bruder et al., 1992; Gille et al., 1995b; Kamano et al., 1995) .
Cell culture and stable transfections
Stromal prostatic cells were derived from pathologically con®ned non-malignant areas of prostatectomy specimens essentially as described by Zhang et al. (1997) . Primary genital skin ®broblasts were cultured as described by Klocker et al. (1992) . PC3 and LNCaP human prostatic carcinoma cell lines were cultured routinely in RPMI medium supplemented with 10% foetal calf serum (FCS) at 378C in a 5% CO 2 atmosphere. All the culture media contained 100 units/ml penicillin and 100 mg/ml streptomycin. PC3 cells were stably transfected with wild-type AR cDNA cloned in the plasmid vector pcDNA3 (Invitrogen) by the calcium phosphate coprecipitation method (PC3 ARwt). Stable transfectants were selected in medium containing 600 mg/ml G418.
Transient transfection assays
Unless otherwise stated, transient transfection was performed according to the calcium phosphate coprecipitation method. For transient transfection assay to determine Elk-1 activity, the cells were cultured 2 h after transfection in RPMI medium supplemented with 0.5% charcoal treated FCS (CCS) and 4.5 mg/ml glucose for a period of 16 h. They were then treated with hormones or with epidermal growth factor (EGF) for an additional 6 h, rinsed twice with cold phosphate buered saline (PBS) and harvested in 400 ml icecold lysis buer (0.1 M Tris-acetate pH 7.5, 2 mM EDTA, 1% v/v Triton X-100). Cellular extracts were prepared and luciferase activity determined with equal amounts of protein. For transactivation studies by the AR, 0.5610 6 LNCaP or PC3 ARwt cells were transfected with 9 mg of pGL3 MMTV, a mouse mammary tumour virus luciferase indicator plasmid (Schneikert et al., 1996) and 1 mg Renilla tk-luciferase plasmid (Promega). After transfection, the cells were treated with DHT or with vehicle (0.1% ethanol) alone for 36 h, harvested, lysed and luciferase assay performed using the Promega dual-luciferase reporter assay system.
PI3 kinase assay
PC3 ARwt cells or PC3 cells stably transfected with an empty vector were cultured for 2 days in RPMI supplemented with 3% CCS. Prior to the addition of inducers, the cells were starved for 3 h in RPMI supplemented with 0.5% CCS and treated with hormone or growth factor. They were then lysed with 1 ml ice-cold buer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 4 mM EGTA, 100 mM NaF, 2 mM Na 3 VO 4 , 10 mM Na 4 P 2 O 7 , 20 mM PMSF, 0.14 mg/ml aprotinin) and centrifuged (10 000 g for 20 min) at 48C. Six hundred microliters of buer (50 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM EGTA, 10% glycerol, 1.5 mM MgCl 2 , 2 mM Na 3 VO 4 ) were added followed by 25 ml protein A-sepharose (Pharmacia Biotech., 1 : 1 in washing buer) and 5 mg anti-phosphotyrosine antibody (4G10, Upstate Biotechnology). Immunoprecipitation was performed overnight at 48C and the protein Asepharose pelleted and washed three times with ice cold washing buer before ®nally resuspending in 50 ml of reaction buer (60 mM Tris pH 7.5, 8 mM MgCl 2 , 100 mM NaCl, 0.5 mM ATP, 10 mCi [g-32 P]ATP) containing 200 mg of the substrate L-a-phosphatidylinositol (Sigma). The reaction was incubated for 10 min at room temperature and stopped by the addition of 150 ml 1 N HCl and the lipids were extracted with 450 ml CHCl 3 /CH 3 OH (1 : 1). The lower phase was dried overnight and the lipid pellet was resuspended in 20 ml CHCl 3 and subjected to a thin-layer chromatography (TLC) (Polygram SilG, Macherey-Nagel) in CHCl 3 /CH 3 OH/acetone/acetic acid/H 2 O (80 : 26 : 30 : 24 : 14) . The radioactively labelled reaction products were visualized by autoradiography.
Immunoblotting
Prior to the MAP kinase assay, the cells were cultured in medium supplemented with 3% CCS for at least 2 days. At 70 ± 80% con¯uence, they were serum-starved for 18 h in medium containing 0.5% CCS and thereafter incubated in fresh medium containing vehicle alone (0.1% ethanol) or vehicle with hormone. They were then harvested, lysed and subjected to a 10% SDS polyacrylamide gel electrophoresis and electroblotted onto PVDF membranes. For detection of the phosphorylated MAP kinases, the membranes were incubated with antibody (New England Biolabs) prior to the addition of a secondary goat anti-rabbit antibody conjugated to horseradish peroxidase and detection by the enhanced chemoluminescence method (ECL, Amersham). Hybridizations with anti-AR and anti-Erk antibodies were performed similarly.
In vitro MAP kinase assay
The cells were washed twice with PBS, lysed in 1 ml lysis buer (30 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 0.5% (w/v) sodium deoxycholate, 10 mM sodium¯uoride, 5 mM sodium orthovanadate, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM PMSF) and the lysates cleared by centrifugation (10 000 g, 15 min at 48C). For immunoprecipitation 30 ml protein A-sepharose and antibody against Erk1 (Santa Cruz) were added to the supernatants and rotated at 48C for 3 h. The antigen-antibody-complexes were pelleted, washed three times with 1 ml lysis buer and once with 1 ml 25 mM Tris pH 8.0. In vitro kinase assay was carried out in a ®nal volume of 50 ml kinase buer (25 mM Tris pH 8.0, 20 mM MgCl 2 , 2 mM MnCl 2 , 1 mM DTT, 5 mg myelin basic protein, 10 mCi [g-32 P]ATP) for 30 min at 308C. The reaction was stopped by addition of 50 ml sample buer (0.16 M Tris pH 6.8, 4% SDS, 20% glycerol, 4% mercaptoethanol, 0.02% bromo-phenol blue) and subjected to a 15% SDS polyacrylamide gel electrophoresis. Thereafter the proteins were transferred onto a PVDF membrane and analysed by autoradiography.
RNA preparation and Northern blot analysis
Poly(A) + RNA preparation and Northern blots were carried out essentially as described by Heck et al. (1997) .
